Side Effects of Shingles and Pneumonia Vaccines
Both shingles and pneumonia vaccines cause primarily local injection site reactions and mild systemic symptoms that resolve within 1-3 days, with the recombinant shingles vaccine (Shingrix) being notably more reactogenic than pneumococcal vaccines.
Shingles Vaccine (Recombinant Zoster Vaccine - Shingrix)
Local Reactions
The most common local side effects at the injection site include 1:
- Pain (75-82%) - most frequent complaint
- Redness (20-28%)
- Swelling (10-17%)
- Severe pain preventing normal activities occurs in 5-11% of recipients
Systemic Reactions
Systemic side effects are notably common with Shingrix 1:
- Myalgia (muscle pain): 37-51%
- Fatigue: 37-51%
- Headache: 15-38%
- Shivering/chills: 11-26%
- Fever ≥99.5°F: 6-28%
- Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain): 13-18%
Important Clinical Note: The second dose of Shingrix typically causes more systemic reactions than the first dose, with median duration of 1-3 days 1. Research confirms these are the most common adverse events, with injection site pain, redness, and swelling being predominant local reactions, while myalgia, fatigue, and headache lead systemic complaints 2.
Serious Events
Serious adverse events are rare (6.6% of reports), with most being non-serious and transient 3. Anaphylaxis occurs at approximately 1 per million doses 3.
Pneumococcal Vaccines
PPSV23 (23-valent Polysaccharide Vaccine)
Local Reactions 4:
- Injection site pain (19.3%)
- Injection site redness (21.1%)
- Injection site swelling (19.3%)
Systemic Reactions: These rates are similar to baseline rates across all adult vaccines, indicating PPSV23 is generally well-tolerated 4. Recent surveillance data from China confirms fever (54 per 100,000 doses) and local redness/swelling (42 per 100,000 doses) as the most common reactions, with 99% occurring within 3 days 5.
Serious Events:
- Anaphylaxis: 1 per million doses
- No pattern of deaths causally associated with PPSV23 4
PCV13/PCV15 (Conjugate Vaccines)
Local and Systemic Reactions 6, 7:
- Injection site tenderness (>80% in children 5-17 years)
- Injection site pain (>50% in adults)
- Fatigue (>30%)
- Headache (>20%)
- Muscle pain (>20%)
- Joint pain (>10%)
- Fever (>5%)
The conjugate vaccines show comparable safety to PPSV23, with most adverse events being mild-to-moderate in severity 7, 8. Serious events occur in only 0.2-1.4% of recipients 7.
Key Clinical Considerations
Comparative Reactogenicity
Shingrix is significantly more reactogenic than pneumococcal vaccines, causing systemic symptoms in 40-80% of recipients versus 5-30% for pneumococcal vaccines. This difference is clinically important for patient counseling.
Co-administration Concerns
When Shingrix is given simultaneously with PPSV23, adverse reactions are more frequently reported 9. Consider separating these vaccines to avoid misattribution of Shingrix's systemic effects to the pneumococcal vaccine, which may reduce future vaccine acceptance 9.
Duration and Management
- Most reactions resolve within 1-3 days across all vaccines 1, 5
- Reactions are typically self-limited and manageable with over-the-counter analgesics
- Counsel patients receiving Shingrix to expect systemic symptoms, particularly after the second dose
Safety Profile Summary
All vaccines demonstrate excellent safety profiles with no unexpected serious adverse events identified in post-marketing surveillance 4, 3, 5. The benefits of disease prevention far outweigh the temporary discomfort from these generally mild, self-limited reactions.